company background image
G0FB logo

Grifols DB:G0FB Stock Report

Last Price

€6.40

Market Cap

€5.4b

7D

-20.0%

1Y

-30.8%

Updated

04 Dec, 2024

Data

Company Financials +

Grifols, S.A. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Grifols
Historical stock prices
Current Share Price€6.40
52 Week High€10.60
52 Week Low€4.78
Beta0.70
11 Month Change-17.95%
3 Month Change-22.42%
1 Year Change-30.81%
33 Year Change-30.75%
5 Year Change-68.93%
Change since IPO-38.09%

Recent News & Updates

Recent updates

Shareholder Returns

G0FBDE BiotechsDE Market
7D-20.0%1.4%3.6%
1Y-30.8%-16.5%9.0%

Return vs Industry: G0FB underperformed the German Biotechs industry which returned -16.5% over the past year.

Return vs Market: G0FB underperformed the German Market which returned 8.6% over the past year.

Price Volatility

Is G0FB's price volatile compared to industry and market?
G0FB volatility
G0FB Average Weekly Movement7.6%
Biotechs Industry Average Movement6.7%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.7%
10% least volatile stocks in DE Market2.4%

Stable Share Price: G0FB's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: G0FB's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
190923,000Nacho Abia Buenachewww.grifols.com

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer’s disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies.

Grifols, S.A. Fundamentals Summary

How do Grifols's earnings and revenue compare to its market cap?
G0FB fundamental statistics
Market cap€5.40b
Earnings (TTM)€161.49m
Revenue (TTM)€7.01b

36.3x

P/E Ratio

0.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
G0FB income statement (TTM)
Revenue€7.01b
Cost of Revenue€4.26b
Gross Profit€2.75b
Other Expenses€2.58b
Earnings€161.49m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.24
Gross Margin39.18%
Net Profit Margin2.31%
Debt/Equity Ratio123.2%

How did G0FB perform over the long term?

See historical performance and comparison